REPOZYTORIUM UNIWERSYTETU
W BIAŁYMSTOKU
UwB

  1. Repozytorium Uniwersytetu w Białymstoku
  2. Wydział Chemii / Faculty of Chemistry
  3. Artykuły naukowe (WChem)

Szukanie zaawansowane
  • Zespoły i Kolekcje


  • Zaloguj się
  • Zarejestruj się
  • Mój RUB
  • FAQ
  • Polityka
  • Regulamin
  • DOI
  • Instrukcja
  • Aspekty prawne
  • Open Access
  • Archiwum


  • Kontakt
  • O Dspace
  • Strona Biblioteki
  • Strona Uczelni



    • Proszę używać tego identyfikatora do cytowań lub wstaw link do tej pozycji: http://hdl.handle.net/11320/19308
    Pełny rekord metadanych
    Pole DCWartośćJęzyk
    dc.contributor.authorMilewska, Sylwia-
    dc.contributor.authorSadowska, Anna-
    dc.contributor.authorStefaniuk, Natalia-
    dc.contributor.authorMisztalewska-Turkowicz, Iwona-
    dc.contributor.authorWilczewska, Agnieszka Z.-
    dc.contributor.authorCar, Halina-
    dc.contributor.authorNiemirowicz-Laskowska, Katarzyna-
    dc.date.accessioned2025-11-25T09:52:30Z-
    dc.date.available2025-11-25T09:52:30Z-
    dc.date.issued2024-
    dc.identifier.citationInternational Journal of Molecular Sciences, Volume 25, Issue 11 (2024), p. 6219-6249pl
    dc.identifier.issn1422-0067-
    dc.identifier.urihttp://hdl.handle.net/11320/19308-
    dc.description.abstractAccording to data from the World Health Organization (WHO), cancer is considered to be one of the leading causes of death worldwide, and new therapeutic approaches, especially improved novel cancer treatment regimens, are in high demand. Considering that many chemotherapeutic drugs tend to have poor pharmacokinetic profiles, including rapid clearance and limited on-site accumulation, a combined approach with tumor-homing peptide (THP)-functionalized magnetic nanoparticles could lead to remarkable improvements. This is confirmed by an increasing number of papers in this field, showing that the on-target peptide functionalization of magnetic nanoparticles improves their penetration properties and ensures tumor-specific binding, which results in an increased clinical response. This review aims to highlight the potential applications of THPs in combination with magnetic carriers across various fields, including a pharmacoeconomic perspective.pl
    dc.description.sponsorshipThis work was financially supported by the National Science Centre, Poland, grant no. NCN/2019/35/B/ST5/03391 (A.Z.W.), and Medical University of Bialystok B.SUB.23.215 (HC), B.SUB.23.258 (AS), and B.SUB.23.257 (KNL).pl
    dc.language.isoenpl
    dc.publisherMDPIpl
    dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Międzynarodowe*
    dc.rights.urihttps:// creativecommons.org/licenses/by/ 4.0/*
    dc.subjecttumor-homing peptidespl
    dc.subjecttargeted deliverypl
    dc.subjecttargeting ligandspl
    dc.subjectdelivery systemspl
    dc.subjectanticancer therapypl
    dc.subjectpharmacoeconomicspl
    dc.subjectclinical analysispl
    dc.subjectcost-effectiveness analysispl
    dc.titleTumor-Homing Peptides as Crucial Component of Magnetic-Based Delivery Systems: Recent Developments and Pharmacoeconomical Perspectivepl
    dc.typeArticlepl
    dc.rights.holder© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).pl
    dc.identifier.doidoi.org/10.3390/ijms25116219-
    dc.description.EmailSylwia Milewska: sylwiakowalewska1@gmail.compl
    dc.description.EmailAnna Sadowska: anna.sadowska@umb.edu.plpl
    dc.description.EmailNatalia Stefaniuk: stefaniuk.natalia99@gmail.compl
    dc.description.EmailIwona Misztalewska-Turkowicz: i.misztalewska@uwb.edu.plpl
    dc.description.EmailAgnieszka Z. Wilczewska: agawilczuwb@gmail.compl
    dc.description.EmailHalina Car: halina.car@umb.edu.plpl
    dc.description.EmailKatarzyna Niemirowicz-Laskowska: katarzyna.niemirowicz-laskowska@umb.edu.plpl
    dc.description.AffiliationSylwia Milewska - Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Polandpl
    dc.description.AffiliationAnna Sadowska - Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Polandpl
    dc.description.AffiliationNatalia Stefaniuk - Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Polandpl
    dc.description.AffiliationIwona Misztalewska-Turkowicz - Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Polandpl
    dc.description.AffiliationAgnieszka Z. Wilczewska - Faculty of Chemistry, University of Bialystok, Ciolkowskiego 1K, 15-245 Bialystok, Polandpl
    dc.description.AffiliationHalina Car - Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Polandpl
    dc.description.AffiliationKatarzyna Niemirowicz-Laskowska - Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Polandpl
    dc.description.referencesKhot, V.M.; Salunkhe, A.B.; Pricl, S.; Bauer, J.; Thorat, N.D.; Townley, H. Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. Drug Discov. Today 2021, 26, 724–739.pl
    dc.description.referencesYavari, B.; Mahjub, R.; Saidijam, M.; Raigani, M.; Soleimani, M. The Potential Use of Peptides in Cancer Treatment. Curr. Protein Pept. Sci. 2018, 19, 759–770.pl
    dc.description.referencesXiao, Y.F.; Jie, M.M.; Li, B.S.; Hu, C.J.; Xie, R.; Tang, B.; Yang, S.M. Peptide-Based Treatment: A Promising Cancer Therapy. J. Immunol. Res. 2015, 2015, 761820.pl
    dc.description.referencesChatzisideri, T.; Leonidis, G.; Sarli, V. Cancer-targeted delivery systems based on peptides. Future Med. Chem. 2018, 10, 2201–2226.pl
    dc.description.referencesTran, S.; DeGiovanni, P.J.; Piel, B.; Rai, P. Cancer nanomedicine: A review of recent success in drug delivery. Clin. Transl. Med. 2017, 6, 44.pl
    dc.description.referencesJain, K.K. Advances in the field of nanooncology. BMC Med. 2010, 8, 83.pl
    dc.description.referencesZhao, C.Y.; Cheng, R.; Yang, Z.; Tian, Z.M. Nanotechnology for Cancer Therapy Based on Chemotherapy. Molecules 2018, 23, 826.pl
    dc.description.referencesYetisgin, A.A.; Cetinel, S.; Zuvin, M.; Kosar, A.; Kutlu, O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules 2020, 25, 2193.pl
    dc.description.referencesHossen, S.; Hossain, M.K.; Basher, M.K.; Mia, M.N.H.; Rahman, M.T.; Uddin, M.J. Smart nanocarrier-based drug delivery systems for cancer therapy and toxicity studies: A review. J. Adv. Res. 2019, 15, 1–18.pl
    dc.description.referencesVangijzegem, T.; Lecomte, V.; Ternad, I.; Van Leuven, L.; Muller, R.N.; Stanicki, D.; Laurent, S. Superparamagnetic Iron Oxide Nanoparticles (SPION): From Fundamentals to State-of-the-Art Innovative Applications for Cancer Therapy. Pharmaceutics 2023, 15, 236.pl
    dc.description.referencesMa, Z.; Mohapatra, J.; Wei, K.; Liu, J.P.; Sun, S. Magnetic Nanoparticles: Synthesis, Anisotropy, and Applications. Chem. Rev. 2023, 123, 3904–3943.pl
    dc.description.referencesVurro, F.; Jabalera, Y.; Mannucci, S.; Glorani, G.; Sola-Leyva, A.; Gerosa, M.; Romeo, A.; Romanelli, M.G.; Malatesta, M.; Calderan, L.; et al. Improving the Cellular Uptake of Biomimetic Magnetic Nanoparticles. Nanomaterials 2021, 11, 766.pl
    dc.description.referencesStevenson, M.; Hale AB, H.; Hale, S.J.; Green, N.K.; Black, G.; Fisher, K.; Ulbrich, K.; Fabra, A.; Seymour, L.W. Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins. Cancer Gene Ther. 2007, 14, 335–345.pl
    dc.description.referencesSoudy, R.; Byeon, N.; Raghuwanshi, Y.; Ahmed, S.; Lavasanifar, A.; Kaur, K. Engineered Peptides for Applications in CancerTargeted Drug Delivery and Tumor Detection. Mini Rev. Med. Chem. 2017, 17, 1696–1712.pl
    dc.description.referencesLee, S.; Xie, J.; Chen, X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010, 49, 1364–1376.pl
    dc.description.referencesColone, M.; Calcabrini, A.; Stringaro, A. Drug Delivery Systems of Natural Products in Oncology. Molecules 2020, 25, 4560.pl
    dc.description.referencesWei, Q.Y.; Xu, Y.M.; Lau, A.T.Y. Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies. Cancers 2020, 12, 2783.pl
    dc.description.referencesChenthamara, D.; Subramaniam, S.; Ramakrishnan, S.G.; Krishnaswamy, S.; Essa, M.M.; Lin, F.H.; Qoronfleh, M.W. Therapeutic efficacy of nanoparticles and routes of administration. Biomater. Res. 2019, 23, 20.pl
    dc.description.referencesDin, F.U.; Aman, W.; Ullah, I.; Qureshi, O.S.; Mustapha, O.; Shafique, S.; Zeb, A. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int. J. Nanomed. 2017, 12, 7291–7309.pl
    dc.description.referencesMitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 2021, 20, 101–124.pl
    dc.description.referencesNavya, P.N.; Kaphle, A.; Srinivas, S.P.; Bhargava, S.K.; Rotello, V.M.; Daima, H.K. Current trends and challenges in cancer management and therapy using designer nanomaterials. Nano Converg. 2019, 6, 23.pl
    dc.description.referencesStueber, D.D.; Villanova, J.; Aponte, I.; Xiao, Z.; Colvin, V.L. Magnetic Nanoparticles in Biology and Medicine: Past, Present, and Future Trends. Pharmaceutics 2021, 13, 943.pl
    dc.description.referencesMorales-Cruz, M.; Delgado, Y.; Castillo, B.; Figueroa, C.M.; Molina, A.M.; Torres, A.; Milián, M.; Griebenow, K. Smart Targeting To Improve Cancer Therapeutics. Drug Des. Devel Ther. 2019, 13, 3753–3772.pl
    dc.description.referencesDissanayake, S.; Denny, W.A.; Gamage, S.; Sarojini, V. Recent developments in anticancer drug delivery using cell penetrating and tumor targeting peptides. J. Control. Release 2017, 250, 62–76.pl
    dc.description.referencesGessner, I.; Neundorf, I. Nanoparticles Modified with Cell-Penetrating Peptides: Conjugation Mechanisms, Physicochemical Properties, and Application in Cancer Diagnosis and Therapy. Int. J. Mol. Sci. 2020, 21, 2536.pl
    dc.description.referencesGautam, A.; Kapoor, P.; Chaudhary, K.; Kumar, R.; Raghava, G.P.; Consortium, O.S.D.D. Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics. Curr. Med. Chem. 2014, 21, 2367–2391.pl
    dc.description.referencesArcangeli, C.; Lico, C.; Baschieri, S.; Mancuso, M. Characterization Of Blood-Brain Barrier Crossing And Tumor Homing Peptides By Molecular Dynamics Simulations. Int. J. Nanomed. 2019, 14, 10123–10136.pl
    dc.description.referencesBor, G.; Hosta-Rigau, L. Next Generation of Brain Cancer Nanomedicines to Overcome the Blood–Brain Barrier (BBB): Insights on Transcytosis, Perivascular Tumor Growth, and BBB Models. Adv. Ther. 2023, 6, 2300161.pl
    dc.description.referencesWanjale, M.V.; Kumar, G.S.V. Peptides as a therapeutic avenue for nanocarrier-aided targeting of glioma. Expert Opin. Drug Deliv. 2017, 14, 811–824.pl
    dc.description.referencesLiu, Y.; Lu, W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin. Drug Deliv. 2012, 9, 671–686.pl
    dc.description.referencesGao, H.; Yang, Z.; Zhang, S.; Cao, S.; Pang, Z.; Yang, X.; Jiang, X. Glioma-homing peptide with a cell-penetrating effect for targeting delivery with enhanced glioma localization, penetration and suppression of glioma growth. J. Control. Release 2013, 172, 921–928.pl
    dc.description.referencesPetho, L.; Mezo, G.; Schlosser, G. Overcharging Effect in Electrospray Ionization Mass Spectra of Daunomycin-Tuftsin Bioconjugates. Molecules 2019, 24, 2981.pl
    dc.description.referencesHu, Y.; Mignani, S.; Majoral, J.-P.; Shen, M.; Shi, X. Construction of iron oxide nanoparticle-based hybrid platforms for tumor imaging and therapy. Chem. Soc. Rev. 2018, 47, 1874–1900.pl
    dc.description.referencesBaranyai, Z.; Biri-Kovács, B.; Krátký, M.; Szeder, B.; Debreczeni, M.L.; Budai, J.; Kovács, B.; Horváth, L.; Pári, E.; Németh, Z.; et al. Cellular Internalization and Inhibition Capacity of New Anti-Glioma Peptide Conjugates: Physicochemical Characterization and Evaluation on Various Monolayer- and 3D-Spheroid-Based in Vitro Platforms. J. Med. Chem. 2021, 64, 2982–3005.pl
    dc.description.referencesvon Wronski, M.A.; Raju, N.; Pillai, R.; Bogdan, N.J.; Marinelli, E.R.; Nanjappan, P.; Ramalingam, K.; Arunachalam, T.; Eaton, S.; Linder, K.E.; et al. Tuftsin Binds Neuropilin-1 through a Sequence Similar to That Encoded by Exon 8 of Vascular Endothelial Growth Factor. J. Biol. Chem. 2006, 281, 5702–5710.pl
    dc.description.referencesRoth, L.; Agemy, L.; Kotamraju, V.R.; Braun, G.; Teesalu, T.; Sugahara, K.N.; Hamzah, J.; Ruoslahti, E. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 2012, 31, 3754–3763.pl
    dc.description.referencesWu, H.B.; Wang, Z.; Wang, Q.S.; Han, Y.J.; Wang, M.; Zhou, W.L.; Li, H.S. Use of Labelled tLyP-1 as a Novel Ligand Targeting the NRP Receptor to Image Glioma. PLoS ONE 2015, 10, e0137676.pl
    dc.description.referencesLarue, L.; Kenzhebayeva, B.; Al-Thiabat, M.G.; Jouan–Hureaux, V.; Mohd–Gazzali, A.; Wahab, H.A.; Boura, C.; Yeligbayeva, G.; Nakan, U.; Frochot, C.; et al. tLyp–1: A peptide suitable to target NRP–1 receptor. Bioorg. Chem. 2023, 130, 106200.pl
    dc.description.referencesMehta, N.; Lyon, J.G.; Patil, K.; Mokarram, N.; Kim, C.; Bellamkonda, R.V. Bacterial Carriers for Glioblastoma Therapy. Mol. Ther.-Oncolytics 2017, 4, 1–17.pl
    dc.description.referencesLi, J.; Feng, L.; Fan, L.; Zha, Y.; Guo, L.; Zhang, Q.; Chen, J.; Pang, Z.; Wang, Y.; Jiang, X.; et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 2011, 32, 4943–4950.pl
    dc.description.referencesRuan, S.; Yuan, M.; Zhang, L.; Hu, G.; Chen, J.; Cun, X.; Zhang, Q.; Yang, Y.; He, Q.; Gao, H. Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 2015, 37, 425–435.pl
    dc.description.referencesPan, L.; He, Q.; Liu, J.; Chen, Y.; Ma, M.; Zhang, L.; Shi, J. Nuclear-Targeted Drug Delivery of TAT Peptide-Conjugated Monodisperse Mesoporous Silica Nanoparticles. J. Am. Chem. Soc. 2012, 134, 5722–5725.pl
    dc.description.referencesJafari, B.; Pourseif, M.M.; Barar, J.; Rafi, M.A.; Omidi, Y. Peptide-mediated drug delivery across the blood-brain barrier for targeting brain tumors. Expert Opin. Drug Deliv. 2019, 16, 583–605.pl
    dc.description.referencesWang, L.; Wang, N.; Zhang, W.; Cheng, X.; Yan, Z.; Shao, G.; Wang, X.; Wang, R.; Fu, C. Therapeutic peptides: Current applications and future directions. Signal Transduct. Target. Ther. 2022, 7, 48.pl
    dc.description.referencesMamelak, A.N.; Jacoby, D.B. Targeted delivery of antitumoral therapy to glioma and other malignancies with synthetic chlorotoxin (TM-601). Expert Opin. Drug Deliv. 2007, 4, 175–186.pl
    dc.description.referencesDardevet, L.; Rani, D.; Aziz, T.A.; Bazin, I.; Sabatier, J.-M.; Fadl, M.; Brambilla, E.; De Waard, M. Chlorotoxin: A Helpful Natural Scorpion Peptide to Diagnose Glioma and Fight Tumor Invasion. Toxins 2015, 7, 1079–1101.pl
    dc.description.referencesCho, C.-F.; Farquhar, C.E.; Fadzen, C.M.; Scott, B.; Zhuang, P.; von Spreckelsen, N.; Loas, A.; Hartrampf, N.; Pentelute, B.L.; Lawler, S.E. A Tumor-Homing Peptide Platform Enhances Drug Solubility, Improves Blood–Brain Barrier Permeability and Targets Glioblastoma. Cancers 2022, 14, 2207.pl
    dc.description.referencesLi, Z.J.; Cho, C.H. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J. Transl. Med. 2012, 10 (Suppl. 1), S1.pl
    dc.description.referencesAnani, T.; Rahmati, S.; Sultana, N.; David, A.E. MRI-traceable theranostic nanoparticles for targeted cancer treatment. Theranostics 2021, 11, 579–601.pl
    dc.description.referencesKoudrina, A.; DeRosa, M.C. Advances in Medical Imaging: Aptamer- and Peptide-Targeted MRI and CT Contrast Agents. ACS Omega 2020, 5, 22691–22701.pl
    dc.description.referencesKondo, E.; Iioka, H.; Saito, K. Tumor-homing peptide and its utility for advanced cancer medicine. Cancer Sci. 2021, 112, 2118–2125.pl
    dc.description.referencesLi, C.; Li, J.; Xu, Y.; Zhan, Y.; Li, Y.; Song, T.; Zheng, J.; Yang, H. Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy. Int. J. Pept. Res. Ther. 2020, 27, 587–595.pl
    dc.description.referencesShubayev, V.I.; Pisanic, T.R.; Jin, S. Magnetic nanoparticles for theragnostics. Adv. Drug Deliv. Rev. 2009, 61, 467–477.pl
    dc.description.referencesJain, T.K.; Richey, J.; Strand, M.; Leslie-Pelecky, D.L.; Flask, C.A.; Labhasetwar, V. Magnetic nanoparticles with dual functional properties: Drug delivery and magnetic resonance imaging. Biomaterials 2008, 29, 4012–4021.pl
    dc.description.referencesLindsley, C.W. Pharmacoeconomics and the medicinal chemist. ACS Med. Chem. Lett. 2014, 5, 1066–1068.pl
    dc.description.referencesLarsen, E.K.; Nielsen, T.; Wittenborn, T.; Rydtoft, L.M.; Lokanathan, A.R.; Hansen, L.; Østergaard, L.; Kingshott, P.; Howard, K.A.; Besenbacher, F.; et al. Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale 2012, 4, 2352–2361.pl
    dc.description.referencesYu, M.; Zheng, J. Clearance Pathways and Tumor Targeting of Imaging Nanoparticles. ACS Nano 2015, 9, 6655–6674.pl
    dc.description.referencesSun, C.; Lee, J.S.H.; Zhang, M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008, 60, 1252–1265.pl
    dc.description.referencesTurrina, C.; Schoenen, M.; Milani, D.; Klassen, A.; Rojas Gonzaléz, D.M.; Cvirn, G.; Mela, P.; Berensmeier, S.; Slabu, I.; Schwaminger, S.P. Application of magnetic iron oxide nanoparticles: Thrombotic activity, imaging and cytocompatibility of silica-coated and carboxymethyl dextrane-coated particles. Colloids Surf. B Biointerfaces 2023, 228, 113428.pl
    dc.description.referencesRarokar, N.; Yadav, S.; Saoji, S.; Bramhe, P.; Agade, R.; Gurav, S.; Khedekar, P.; Subramaniyan, V.; Wong, L.S.; Kumarasamy, V. Magnetic nanosystem a tool for targeted delivery and diagnostic application: Current challenges and recent advancement. Int. J. Pharm. X 2024, 7, 100231.pl
    dc.description.referencesDadfar, S.M.; Roemhild, K.; Drude, N.I.; von Stillfried, S.; Knüchel, R.; Kiessling, F.; Lammers, T. Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 2019, 138, 302–325.pl
    dc.description.referencesChen, Y.; Hou, S. Recent progress in the effect of magnetic iron oxide nanoparticles on cells and extracellular vesicles. Cell Death Discov. 2023, 9, 195.pl
    dc.description.referencesPatel, P.; Nandi, A.; Jha, E.; Sinha, A.; Mohanty, S.; Panda, P.K.; Mishra, S.; Verma, S.K.; Suar, M. 2—Magnetic nanoparticles: Fabrication, characterization, properties, and application for environment sustainability. In Magnetic Nanoparticle-Based Hybrid Materials; Ehrmann, A., Nguyen, T.A., Ahmadi, M., Farmani, A., Nguyen-Tri, P., Eds.; Woodhead Publishing: Sawston, UK, 2021; pp. 33–64.pl
    dc.description.referencesLing, D.; Lee, N.; Hyeon, T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc. Chem. Res. 2015, 48, 1276–1285.pl
    dc.description.referencesPróspero, A.G.; Quini, C.C.; Bakuzis, A.F.; Fidelis-de-Oliveira, P.; Moretto, G.M.; Mello, F.P.; Calabresi, M.F.; Matos, R.V.; Zandoná, E.A.; Zufelato, N.; et al. Real-time in vivo monitoring of magnetic nanoparticles in the bloodstream by AC biosusceptometry. J. Nanobiotechnology 2017, 15, 22.pl
    dc.description.referencesMilewska, S.; Niemirowicz-Laskowska, K.; Siemiaszko, G.; Nowicki, P.; Wilczewska, A.Z.; Car, H. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. Int. J. Nanomed. 2021, 16, 6593–6644.pl
    dc.description.referencesGan, Z.F.; Jiang, J.S.; Yang, Y.; Du, B.; Qian, M.; Zhang, P. Immobilization of homing peptide on magnetite nanoparticles and its specificity in vitro. J. Biomed. Mater. Res. A 2008, 84, 10–18.pl
    dc.description.referencesMorita, Y.; Sakurai, R.; Wakimoto, T.; Kobayashi, K.; Xu, B.; Toku, Y.; Song, G.; Luo, Q.; Ju, Y. TLyP-1-Conjugated Core-Shell Nanoparticles, Fe3O4NPs@mSiO2, for Tumor-Targeted Drug Delivery. Appl. Surf. Sci. 2019, 474, 17–24.pl
    dc.description.referencesNiemirowicz, K.; Prokop, I.; Wilczewska, A.Z.; Wnorowska, U.; Piktel, E.; W ˛atek, M.; Savage, P.B.; Bucki, R. Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells. Int. J. Nanomed. 2015, 10, 3843–3853.pl
    dc.description.referencesKong, F.; Bai, H.; Ma, M.; Wang, C.; Xu, H.; Gu, N.; Zhang, Y. Fe3O4@Pt Nanozymes Combining with CXCR4 Antagonists to Synergistically Treat Acute Myeloid Leukemia. Nano Today 2021, 37, 101106.pl
    dc.description.referencesHamilton, A.M.; Aidoudi-Ahmed, S.; Sharma, S.; Kotamraju, V.R.; Foster, P.J.; Sugahara, K.N.; Ruoslahti, E.; Rutt, B.K. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. J. Mol. Med. 2015, 93, 991–1001.pl
    dc.description.referencesChen, K.; Xie, J.; Xu, H.; Behera, D.; Michalski, M.H.; Biswal, S.; Wang, A.; Chen, X. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials 2009, 30, 6912–6919.pl
    dc.description.referencesSharma, S.; Kotamraju, V.R.; Mölder, T.; Tobi, A.; Teesalu, T.; Ruoslahti, E. Tumor-Penetrating Nanosystem Strongly Suppresses Breast Tumor Growth. Nano Lett. 2017, 17, 1356–1364.pl
    dc.description.referencesSharma, S.; Mann, A.P.; Mölder, T.; Kotamraju, V.R.; Mattrey, R.; Teesalu, T.; Ruoslahti, E. Vascular changes in tumors resistant to a vascular disrupting nanoparticle treatment. J. Control. Release 2017, 268, 49–56.pl
    dc.description.referencesChen, X.; Wang, Q.; Liu, L.; Sun, T.; Zhou, W.; Chen, Q.; Lu, Y.; He, X.; Zhang, Y.; Ruan, C.; et al. Double-sided effect of tumor microenvironment on platelets targeting nanoparticles. Biomaterials 2018, 183, 258–267.pl
    dc.description.referencesJiang, J.; Gan, Z.; Yang, Y.; Bing, D.; Min, Q.; Ping, Z. A Novel Magnetic Fluid Based on Starch-Coated Mgnetite Nanoparticles Functionalized with Homing Peptide. J. Nanoparticle Res. 2009, 11, 1321–1330.pl
    dc.description.referencesRuoslahti, E. Tumor penetrating peptides for improved drug delivery. Adv. Drug Deliv. Rev. 2017, 110–111, 3–12.pl
    dc.description.referencesJie, L.Y.; Cai, L.L.; Wang, L.J.; Ying, X.Y.; Yu, R.S.; Zhang, M.M.; Du, Y.Z. Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging. Int. J. Nanomed. 2012, 7, 3981–3989.pl
    dc.description.referencesSitu, J.Q.; Wang, X.J.; Zhu, X.L.; Xu, X.L.; Kang, X.Q.; Hu, J.B.; Lu, C.Y.; Ying, X.Y.; Yu, R.S.; You, J.; et al. Multifunctional SPIO/DOX-loaded A54 Homing Peptide Functionalized Dextran-g-PLGA Micelles for Tumor Therapy and MR Imaging. Sci. Rep. 2016, 6, 35910.pl
    dc.description.referencesHuang, Y.W.; Lee, H.J.; Tolliver, L.M.; Aronstam, R.S. Delivery of nucleic acids and nanomaterials by cell-penetrating peptides: Opportunities and challenges. BioMed. Res. Int. 2015, 2015, 834079.pl
    dc.description.referencesJones, S.; Uusna, J.; Langel, Ü.; Howl, J. Intracellular Target-Specific Accretion of Cell Penetrating Peptides and Bioportides: Ultrastructural and Biological Correlates. Bioconjugate Chem. 2016, 27, 121–129.pl
    dc.description.referencesRaucher, D.; Ryu, J.S. Cell-penetrating peptides: Strategies for anticancer treatment. Trends Mol. Med. 2015, 21, 560–570.pl
    dc.description.referencesBruno, B.J.; Miller, G.D.; Lim, C.S. Basics and recent advances in peptide and protein drug delivery. Ther. Deliv. 2013, 4, 1443–1467.pl
    dc.description.referencesZhu, X.; Lu, N.; Zhou, Y.; Xuan, S.; Zhang, J.; Giampieri, F.; Zhang, Y.; Yang, F.; Yu, R.; Battino, M.; et al. Targeting Pancreatic Cancer Cells with Peptide-Functionalized Polymeric Magnetic Nanoparticles. Int. J. Mol. Sci. 2019, 20, 2988.pl
    dc.description.referencesLuo, Z.; Du, H. Prospect of Different Types of Magnetic Nanoparticles in Stem Cell Therapy. Stem Cell Rev. Rep. 2020, 16, 675–683.pl
    dc.description.referencesScarberry, K.E.; Dickerson, E.B.; McDonald, J.F.; Zhang, Z.J. Magnetic nanoparticle-peptide conjugates for in vitro and in vivo targeting and extraction of cancer cells. J. Am. Chem. Soc. 2008, 130, 10258–10262.pl
    dc.description.referencesSimberg, D.; Duza, T.; Park, J.H.; Essler, M.; Pilch, J.; Zhang, L.; Derfus, A.M.; Yang, M.; Hoffman, R.M.; Bhatia, S.; et al. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA 2007, 104, 932–936.pl
    dc.description.referencesLaakkonen, P.; Vuorinen, K. Homing peptides as targeted delivery vehicles. Integr. Biol. 2010, 2, 326–337.pl
    dc.description.referencesGandhi, S.; Arami, H.; Krishnan, K.M. Detection of Cancer-Specific Proteases Using Magnetic Relaxation of Peptide-Conjugated Nanoparticles in Biological Environment. Nano Lett. 2016, 16, 3668–3674.pl
    dc.description.referencesRastogi, A.; Yadav, K.; Mishra, A.; Singh, M.S.; Chaudhary, S.; Manohar, R.; Parmar, A.S. Early diagnosis of lung cancer using magnetic nanoparticles-integrated systems. Nanotechnol. Rev. 2022, 11, 544–574.pl
    dc.description.referencesCrezee, J.; Franken, N.A.P.; Oei, A.L. Hyperthermia-Based Anti-Cancer Treatments. Cancers 2021, 13, 1240.pl
    dc.description.referencesDatta, N.R.; Ordóñez, S.G.; Gaipl, U.S.; Paulides, M.M.; Crezee, H.; Gellermann, J.; Marder, D.; Puric, E.; Bodis, S. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treat. Rev. 2015, 41, 742–753.pl
    dc.description.referencesBehrouzkia, Z.; Joveini, Z.; Keshavarzi, B.; Eyvazzadeh, N.; Aghdam, R.Z. Hyperthermia: How Can It Be Used? Oman Med. J. 2016, 31, 89–97.pl
    dc.description.referencesGong, L.; Zhang, Y.; Liu, C.; Zhang, M.; Han, S. Application of Radiosensitizers in Cancer Radiotherapy. Int. J. Nanomed. 2021, 16, 1083–1102.pl
    dc.description.referencesRoizin-Towle, L.; Pirro, J.P. The response of human and rodent cells to hyperthermia. Int. J. Radiat. Oncol. Biol. Phys. 1991, 20, 751–756.pl
    dc.description.referencesGavilán, H.; Avugadda, S.K.; Fernández-Cabada, T.; Soni, N.; Cassani, M.; Mai, B.T.; Chantrell, R.; Pellegrino, T. Magnetic nanoparticles and clusters for magnetic hyperthermia: Optimizing their heat performance and developing combinatorial therapies to tackle cancer. Chem. Soc. Rev. 2021, 50, 11614–11667.pl
    dc.description.referencesShetake, N.G.; Ali, M.; Kumar, A.; Bellare, J.; Pandey, B.N. Theranostic magnetic nanoparticles enhance DNA damage and mitigate doxorubicin-induced cardio-toxicity for effective multi-modal tumor therapy. Biomater. Adv. 2022, 142, 213147.pl
    dc.description.referencesArriortua, O.K.; Insausti, M.; Lezama, L.; Gil de Muro, I.; Garaio, E.; de la Fuente, J.M.; Fratila, R.M.; Morales, M.P.; Costa, R.; Eceiza, M.; et al. RGD-Functionalized Fe(3)O(4) nanoparticles for magnetic hyperthermia. Colloids Surf. B Biointerfaces 2018, 165, 315–324.pl
    dc.description.referencesSeyyednia, E.; Oroojalian, F.; Baradaran, B.; Mojarrad, J.S.; Mokhtarzadeh, A.; Valizadeh, H. Nanoparticles modified with vasculature-homing peptides for targeted cancer therapy and angiogenesis imaging. J. Control. Release 2021, 338, 367–393.pl
    dc.description.referencesArriortua, O.K.; Garaio, E.; Herrero de la Parte, B.; Insausti, M.; Lezama, L.; Plazaola, F.; García, J.A.; Aizpurua, J.M.; Sagartzazu, M.; Irazola, M.; et al. Antitumor magnetic hyperthermia induced by RGD-functionalized Fe(3)O(4) nanoparticles, in an experimental model of colorectal liver metastases. Beilstein J. Nanotechnol. 2016, 7, 1532–1542.pl
    dc.description.referencesSadhukha, T.; Wiedmann, T.S.; Panyam, J. Inhalable magnetic nanoparticles for targeted hyperthermia in lung cancer therapy. Biomaterials 2013, 34, 5163–5171.pl
    dc.description.referencesNica, V.; Marino, A.; Pucci, C.; ¸Sen, Ö.; Emanet, M.; De Pasquale, D.; Carmignani, A.; Petretto, A.; Bartolucci, M.; Lauciello, S.; et al. Cell-Membrane-Coated and Cell-Penetrating Peptide-Conjugated Trimagnetic Nanoparticles for Targeted Magnetic Hyperthermia of Prostate Cancer Cells. ACS Appl. Mater. Interfaces 2023, 15, 30008–30028.pl
    dc.description.referencesPerillo, E.; Hervé-Aubert, K.; Allard-Vannier, E.; Falanga, A.; Galdiero, S.; Chourpa, I. Synthesis and in vitro evaluation of fluorescent and magnetic nanoparticles functionalized with a cell penetrating peptide for cancer theranosis. J. Colloid. Interface Sci. 2017, 499, 209–217.pl
    dc.description.referencesZhang, W.; Taheri-Ledari, R.; Hajizadeh, Z.; Zolfaghari, E.; Ahghari, M.R.; Maleki, A.; Hamblin, M.R.; Tian, Y. Enhanced activity of vancomycin by encapsulation in hybrid magnetic nanoparticles conjugated to a cell-penetrating peptide. Nanoscale 2020, 12, 3855–3870.pl
    dc.description.referencesChaix, A.; Griveau, A.; Defforge, T.; Grimal, V.; Le Borgne, B.; Gautier, G.; Eyer, J. Cell penetrating peptide decorated magnetic porous silicon nanorods for glioblastoma therapy and imaging. RSC Adv. 2022, 12, 11708–11714.pl
    dc.description.referencesShrestha, R.; Shen, Y.; Pollack, K.A.; Taylor, J.S.; Wooley, K.L. Dual peptide nucleic acid- and peptide-functionalized shell cross-linked nanoparticles designed to target mRNA toward the diagnosis and treatment of acute lung injury. Bioconjugate Chem. 2012, 23, 574–585.pl
    dc.description.referencesHauser, A.K.; Anderson, K.W.; Hilt, J.Z. Peptide conjugated magnetic nanoparticles for magnetically mediated energy delivery to lung cancer cells. Nanomedicine 2016, 11, 1769–1785.pl
    dc.description.referencesHalouane, F.; Jijie, R.; Meziane, D.; Li, C.; Singh, S.K.; Bouckaert, J.; Jurazek, J.; Kurungot, S.; Barras, A.; Li, M.; et al. Selective isolation and eradication of E. coli associated with urinary tract infections using anti-fimbrial modified magnetic reduced graphene oxide nanoheaters. J. Mater. Chem. B 2017, 5, 8133–8142.pl
    dc.description.referencesAttari, E.; Nosrati, H.; Danafar, H.; Kheiri Manjili, H. Methotrexate anticancer drug delivery to breast cancer cell lines by iron oxide magnetic based nanocarrier. J. Biomed. Mater. Res. A 2019, 107, 2492–2500.pl
    dc.description.referencesVadevoo, S.M.P.; Gurung, S.; Lee, H.-S.; Gunassekaran, G.R.; Lee, S.-M.; Yoon, J.-W.; Lee, Y.-K.; Lee, B. Peptides as multifunctional players in cancer therapy. Exp. Mol. Med. 2023, 55, 1099–1109.pl
    dc.description.referencesClinicalTrials.gov. Available online: https://clinicaltrials.gov/ (accessed on 24 March 2024).pl
    dc.description.referencesInternational Clinical Trials; ICTRP Search Portal. 2024. Available online: https://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal (accessed on 24 March 2024).pl
    dc.description.references68Ga- THP- PSMA PET/CT Imaging in High Risk Primary Prostate Cancer or Biochemical Recurrence of Prostate Cancer (PRONOUNCED). 12 June 2019. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT03617588 (accessed on 24 March 2024).pl
    dc.description.referencesPre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study. April 2016. Available online: https: //classic.clinicaltrials.gov/ProvidedDocs/33/NCT01815333/Prot_SAP_000.pdf (accessed on 24 March 2024).pl
    dc.description.referencesClinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging. June 2019. Available online: https://www.clinicaltrials.gov/study/NCT01815333 (accessed on 24 March 2024).pl
    dc.description.referencesPre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI). February 2013. Available online: https://classic.clinicaltrials.gov/ct2/show/NCT00920023 (accessed on 24 March 2024).pl
    dc.description.referencesKim, J.; Kim, P.H.; Kim, S.W.; Yun, C.O. Enhancing the therapeutic efficacy of adenovirus in combination with biomaterials. Biomaterials 2012, 33, 1838–1850pl
    dc.description.referencesThundimadathil, J. Cancer treatment using peptides: Current therapies and future prospects. J. Amino Acids 2012, 2012, 967347.pl
    dc.description.referencesLi, C.; Wang, J.; Wang, Y.; Gao, H.; Wei, G.; Huang, Y.; Yu, H.; Gan, Y.; Mei, L.; Chen, H.; et al. Recent progress in drug delivery. Acta Pharm. Sin. B 2019, 9, 1145–1162.pl
    dc.description.referencesCutrera, J.; Dibra, D.; Xia, X.; Hasan, A.; Reed, S.; Li, S. Discovery of a linear peptide for improving tumor targeting of gene products and treatment of distal tumors by IL-12 gene therapy. Mol. Ther. 2011, 19, 1468–1477.pl
    dc.description.referencesWu, C.; Zhang, Y.; Wei, X.; Li, N.; Huang, H.; Xie, Z.; Zhang, H.; Yang, G.; Li, M.; Li, T.; et al. Tumor homing-penetrating and nanoenzyme-augmented 2D phototheranostics against hypoxic solid tumors. Acta Biomater. 2022, 150, 391–401.pl
    dc.description.referencesSorolla, A.; Wang, E.; Golden, E.; Duffy, C.; Henriques, S.T.; Redfern, A.D.; Blancafort, P. Precision medicine by designer interference peptides: Applications in oncology and molecular therapeutics. Oncogene 2020, 39, 1167–1184.pl
    dc.description.referencesLiscano, Y.; Oñate-Garzón, J.; Delgado, J.P. Peptides with Dual Antimicrobial-Anticancer Activity: Strategies to Overcome Peptide Limitations and Rational Design of Anticancer Peptides. Molecules 2020, 25, 4245.pl
    dc.description.referencesPatra, J.K.; Das, G.; Fraceto, L.F.; Campos, E.V.R.; Rodriguez-Torres, M.D.P.; Acosta-Torres, L.S.; Diaz-Torres, L.A.; Grillo, R.; Swamy, M.K.; Sharma, S.; et al. Nano based drug delivery systems: Recent developments and future prospects. J. Nanobiotechnology 2018, 16, 1–33.pl
    dc.description.referencesMuro, E.; Atilla-Gokcumen, G.E.; Eggert, U.S. Lipids in cell biology: How can we understand them better? Mol. Biol. Cell 2014, 25, 1819–1823.pl
    dc.description.referencesSantos, A.L.; Preta, G. Lipids in the cell: Organisation regulates function. Cell Mol. Life Sci. 2018, 75, 1909–1927.pl
    dc.description.referencesSezgin, E.; Levental, I.; Mayor, S.; Eggeling, C. The mystery of membrane organization: Composition, regulation and roles of lipid rafts. Nat. Rev. Mol. Cell Biol. 2017, 18, 361–374.pl
    dc.description.referencesLi, C.M.; Haratipour, P.; Lingeman, R.G.; Perry, J.J.P.; Gu, L.; Hickey, R.J.; Malkas, L.H. Novel Peptide Therapeutic Approaches for Cancer Treatment. Cells 2021, 10, 2908.pl
    dc.description.referencesYamaji-Hasegawa, A.; Tsujimoto, M. Asymmetric distribution of phospholipids in biomembranes. Biol. Pharm. Bull. 2006, 29, 1547–1553.pl
    dc.description.referencesRan, S.; Downes, A.; Thorpe, P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62, 6132–6140.pl
    dc.description.referencesStafford, J.H.; Thorpe, P.E. Increased exposure of phosphatidylethanolamine on the surface of tumor vascular endothelium. Neoplasia 2011, 13, 299–308.pl
    dc.description.referencesBarceló-Coblijn, G.; Martin, M.L.; de Almeida, R.F.; Noguera-Salvà, M.A.; Marcilla-Etxenike, A.; Guardiola-Serrano, F.; Lüth, A.; Kleuser, B.; Halver, J.E.; Escribá, P.V. Sphingomyelin and sphingomyelin synthase (SMS) in the malignant transformation of glioma cells and in 2-hydroxyoleic acid therapy. Proc. Natl. Acad. Sci. USA 2011, 108, 19569–19574.pl
    dc.description.referencesPreetha, A.; Huilgol, N.; Banerjee, R. Comparison of paclitaxel penetration in normal and cancerous cervical model monolayer membranes. Colloids Surf. B Biointerfaces 2006, 53, 179–186.pl
    dc.description.referencesZhao, L.; Feng, S.S.; Go, M.L. Investigation of molecular interactions between paclitaxel and DPPC by Langmuir film balance and differential scanning calorimetry. J. Pharm. Sci. 2004, 93, 86–98.pl
    dc.description.referencesChiangjong, W.; Chutipongtanate, S.; Hongeng, S. Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review). Int. J. Oncol. 2020, 57, 678–696.pl
    dc.description.referencesLogozzi, M.; Spugnini, E.; Mizzoni, D.; Di Raimo, R.; Fais, S. Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer Metastasis Rev. 2019, 38, 93–101.pl
    dc.description.referencesCardone, R.A.; Casavola, V.; Reshkin, S.J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer 2005, 5, 786–795.pl
    dc.description.referencesBernardes, N.; Fialho, A.M. Perturbing the Dynamics and Organization of Cell Membrane Components: A New Paradigm for Cancer-Targeted Therapies. Int. J. Mol. Sci. 2018, 19, 3871.pl
    dc.description.referencesEscribá, P.V. Membrane-lipid therapy: A historical perspective of membrane-targeted therapies—From lipid bilayer structure to the pathophysiological regulation of cells. Biochim. Biophys. Acta Biomembr. 2017, 1859, 1493–1506.pl
    dc.description.referencesHoskin, D.W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides. Biochim. Biophys. Acta 2008, 1778, 357–375.pl
    dc.description.referencesRodrigues, E.G.; Dobroff, A.S.; Taborda, C.P.; Travassos, L.R. Antifungal and antitumor models of bioactive protective peptides. An. Acad. Bras. Cienc. 2009, 81, 503–520.pl
    dc.description.referencesDroin, N.; Hendra, J.B.; Ducoroy, P.; Solary, E. Human defensins as cancer biomarkers and antitumour molecules. J. Proteom. 2009, 72, 918–927.pl
    dc.description.referencesSimons, K.; Ikonen, E. How cells handle cholesterol. Science 2000, 290, 1721–1726.pl
    dc.description.referencesHarris, F.; Dennison, S.R.; Singh, J.; Phoenix, D.A. On the selectivity and efficacy of defense peptides with respect to cancer cells. Med. Res. Rev. 2013, 33, 190–234.pl
    dc.description.referencesLi, X.; Ding, J.; Wang, X.; Wei, K.; Weng, J.; Wang, J. One-pot synthesis and functionalisation of Fe2O3@C-NH2 nanoparticles for imaging and therapy. IET Nanobiotechnol. 2014, 8, 93–101.pl
    dc.description.referencesHoppenz, P.; Els-Heindl, S.; Beck-Sickinger, A.G. Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. Front. Chem. 2020, 8, 571.pl
    dc.description.referencesEHJ, D. Integrins: An Overview of Structural and Functional Aspects. In Madame Curie Bioscience Database [Internet]; Landes Bioscience: Austin, TX, USA, 2000–2013.pl
    dc.description.referencesLiu, Z.; Wang, F.; Chen, X. Integrin alpha(v)beta(3)-Targeted Cancer Therapy. Drug Dev. Res. 2008, 69, 329–339.pl
    dc.description.referencesSeshacharyulu, P.; Ponnusamy, M.P.; Haridas, D.; Jain, M.; Ganti, A.K.; Batra, S.K. Targeting the EGFR signaling pathway in cancer therapy. Expert Opin. Ther. Targets 2012, 16, 15–31.pl
    dc.description.referencesSriram, K.; Insel, P.A. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? Mol. Pharmacol. 2018, 93, 251–258.pl
    dc.description.referencesBasith, S.; Cui, M.; Macalino, S.J.Y.; Park, J.; Clavio, N.A.B.; Kang, S.; Choi, S. Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design. Front. Pharmacol. 2018, 9, 128.pl
    dc.description.referencesLu, Z.X.; Liu, L.T.; Qi, X.R. Development of small interfering RNA delivery system using PEI-PEG-APRPG polymer for antiangiogenic vascular endothelial growth factor tumor-targeted therapy. Int. J. Nanomed. 2011, 6, 1661–1673.pl
    dc.description.referencesHao, Z.; Fan, W.; Hao, J.; Wu, X.; Zeng, G.Q.; Zhang, L.J.; Nie, S.F.; Wang, X.D. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv. 2016, 23, 874–881.pl
    dc.description.referencesGostaviceanu, A.; Gavrila¸s, S.; Copolovici, L.; Copolovici, D.M. Membrane-Active Peptides and Their Potential Biomedical Application. Pharmaceutics 2023, 15, 2091.pl
    dc.description.referencesDavid, A. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv. Drug Deliv. Rev. 2017, 119, 120–142.pl
    dc.description.referencesD’Onofrio, N.; Caraglia, M.; Grimaldi, A.; Marfella, R.; Servillo, L.; Paolisso, G.; Balestrieri, M.L. Vascular-homing peptides for targeted drug delivery and molecular imaging: Meeting the clinical challenges. Biochim. Biophys. Acta 2014, 1846, 1–12.pl
    dc.description.referencesGhabraie, E.; Kemker, I.; Tonali, N.; Ismail, M.; Dodero, V.I.; Sewald, N. Phenothiazine-Biaryl-Containing Fluorescent RGD Peptides. Chemistry 2020, 26, 12036–12042.pl
    dc.description.referencesLiolios, C.; Sachpekidis, C.; Kolocouris, A.; Dimitrakopoulou-Strauss, A.; Bouziotis, P. PET Diagnostic Molecules Utilizing Multimeric Cyclic RGD Peptide Analogs for Imaging Integrin α. Molecules 2021, 26, 1792.pl
    dc.description.referencesShi, J.; Wang, F.; Liu, S. Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging. Biophys. Rep. 2016, 2, 1–20.pl
    dc.description.referencesZuo, H. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers. J. Oncol. 2019, 2019, 9367845.pl
    dc.description.referencesCho, H.J.; Lee, S.J.; Park, S.J.; Paik, C.H.; Lee, S.M.; Kim, S.; Lee, Y.S. Activatable iRGD-based peptide monolith: Targeting, internalization, and fluorescence activation for precise tumor imaging. J. Control. Release 2016, 237, 177–184.pl
    dc.description.referencesYin, H.; Yang, J.; Zhang, Q.; Wang, H.; Xu, J.; Zheng, J. iRGD as a tumor-penetrating peptide for cancer therapy (Review). Mol. Med. Rep. 2017, 15, 2925–2930.pl
    dc.description.referencesSugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Girard, O.M.; Hanahan, D.; Mattrey, R.F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16, 510–520.pl
    dc.description.referencesSugahara, K.N.; Braun, G.B.; de Mendoza, T.H.; Kotamraju, V.R.; French, R.P.; Lowy, A.M.; Teesalu, T.; Ruoslahti, E. Tumorpenetrating iRGD peptide inhibits metastasis. Mol. Cancer Ther. 2015, 14, 120–128.pl
    dc.description.referencesTeesalu, T.; Sugahara, K.N.; Kotamraju, V.R.; Ruoslahti, E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. USA 2009, 106, 16157–16162.pl
    dc.description.referencesWang, Y.; Xie, Y.; Li, J.; Peng, Z.H.; Sheinin, Y.; Zhou, J.; Oupický, D. Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy. ACS Nano 2017, 11, 2227–2238.pl
    dc.description.referencesSugahara, K.N.; Teesalu, T.; Karmali, P.P.; Kotamraju, V.R.; Agemy, L.; Greenwald, D.R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010, 328, 1031–1035.pl
    dc.description.referencesPellinen, T.; Ivaska, J. Integrin traffic. J. Cell Sci. 2006, 119, 3723–3731.pl
    dc.description.referencesYao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Narimatsu, S.; Kawai, Y.; Mizuguchi, H.; Gao, J.Q.; Mukai, Y.; Okada, N.; et al. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy. Mol. Ther. 2011, 19, 1619–1625.pl
    dc.description.referencesZuo, H.D.; Yao, W.W.; Chen, T.W.; Zhu, J.; Zhang, J.J.; Pu, Y.; Liu, G.; Zhang, X.M. The effect of superparamagnetic iron oxide with iRGD peptide on the labeling of pancreatic cancer cells in vitro: A preliminary study. BioMed. Res. Int. 2014, 2014, 852352.pl
    dc.description.referencesSeidi, K.; Jahanban-Esfahlan, R.; Monhemi, H.; Zare, P.; Minofar, B.; Daei Farshchi Adli, A.; Farajzadeh, D.; Behzadi, R.; Mesgari Abbasi, M.; Neubauer, H.A.; et al. NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth. Oncogene 2018, 37, 3967–3980.pl
    dc.description.referencesSeidi, K.; Neubauer, H.A.; Moriggl, R.; Jahanban-Esfahlan, R.; Javaheri, T. Tumor target amplification: Implications for nano drug delivery systems. J. Control. Release 2018, 275, 142–161.pl
    dc.description.referencesZhu, L.; Ding, Z.; Li, X.; Wei, H.; Chen, Y. Research Progress of Radiolabeled Asn-Gly-Arg (NGR) Peptides for Imaging and Therapy. Mol. Imaging 2020, 19, 1536012120934957.pl
    dc.description.referencesCosta, D.; Santo, D.; Domingues, C.; Veiga, F.; Faneca, H.; Figueiras, A. Recent advances in peptide-targeted micelleplexes: Current developments and future perspectives. Int. J. Pharm. 2021, 597, 120362.pl
    dc.description.referencesFelício, M.R.; Silva, O.N.; Gonçalves, S.; Santos, N.C.; Franco, O.L. Peptides with Dual Antimicrobial and Anticancer Activities. Front. Chem. 2017, 5, 5.pl
    dc.description.referencesKebebe, D.; Liu, Y.; Wu, Y.; Vilakhamxay, M.; Liu, Z.; Li, J. Tumor-targeting delivery of herb-based drugs with cellpenetrating/tumor-targeting peptide-modified nanocarriers. Int. J. Nanomed. 2018, 13, 1425–1442.pl
    dc.description.referencesCiobanasu, C.; Dragomir, I.; Apetrei, A. The penetrating properties of the tumor homing peptide LyP-1 in model lipid membranes. J. Pept. Sci. 2019, 25, e3145.pl
    dc.description.referencesTaylor, R.E.; Zahid, M. Cell Penetrating Peptides, Novel Vectors for Gene Therapy. Pharmaceutics 2020, 12, 225.pl
    dc.description.referencesPaulus, J.; Sewald, N. Small molecule– and peptide–drug conjugates addressing integrins: A story of targeted cancer treatment. J. Pept. Sci. 2024, 30, e3561.pl
    dc.description.referencesSharma, A.; Kapoor, P.; Gautam, A.; Chaudhary, K.; Kumar, R.; Chauhan, J.S.; Tyagi, A.; Raghava, G.P.S. Computational approach for designing tumor homing peptides. Sci. Rep. 2013, 3, 1607.pl
    dc.description.referencesShoombuatong, W.; Schaduangrat, N.; Pratiwi, R.; Nantasenamat, C. THPep: A machine learning-based approach for predicting tumor homing peptides. Comput. Biol. Chem. 2019, 80, 441–451.pl
    dc.description.referencesCharoenkwan, P.; Chiangjong, W.; Nantasenamat, C.; Moni, M.A.; Lio’, P.; Manavalan, B.; Shoombuatong, W. SCMTHP: A New Approach for Identifying and Characterizing of Tumor-Homing Peptides Using Estimated Propensity Scores of Amino Acids. Pharmaceutics 2022, 14, 122.pl
    dc.description.referencesGuan, J.; Yao, L.; Chung, C.-R.; Chiang, Y.-C.; Lee, T.-Y. StackTHPred: Identifying Tumor-Homing Peptides through GBDT-Based Feature Selection with Stacking Ensemble Architecture. Int. J. Mol. Sci. 2023, 24, 10348.pl
    dc.description.referencesZou, H.; Yang, F.; Yin, Z. Identification of tumor homing peptides by utilizing hybrid feature representation. J. Biomol. Struct. Dyn. 2023, 41, 3405–3412.pl
    dc.description.referencesCharoenkwan, P.; Schaduangrat, N.; Lio, P.; Moni, M.A.; Manavalan, B.; Shoombuatong, W. NEPTUNE: A novel computational approach for accurate and large-scale identification of tumor homing peptides. Comput. Biol. Med. 2022, 148, 105700.pl
    dc.description.referencesRomero, M.; Marrero-Ponce, Y.; Rodríguez, H.; Agüero-Chapin, G.; Antunes, A.; Aguilera-Mendoza, L.; Martinez-Rios, F. A Novel Network Science and Similarity-Searching-Based Approach for Discovering Potential Tumor-Homing Peptides from Antimicrobials. Antibiotics 2022, 11, 401.pl
    dc.description.referencesLiu, M.; Fang, X.; Yang, Y.; Wang, C. Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications. Front. Bioeng. Biotechnol. 2021, 9, 701504.pl
    dc.description.referencesSvensen, N.; Walton, J.G.; Bradley, M. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 2012, 33, 186–192.pl
    dc.description.referencesMaeda, M.; Kida, S.; Hojo, K.; Eto, Y.; Gaob, J.Q.; Kurachi, S.; Sekiguchi, F.; Mizuguchi, H.; Hayakawa, T.; Mayumi, T.; et al. Design and synthesis of a peptide-PEG transporter tool for carrying adenovirus vector into cells. Bioorg. Med. Chem. Lett. 2005, 15, 621–624.pl
    dc.description.referencesOgawara, K.; Kułdo, J.M.; Oosterhuis, K.; Kroesen, B.J.; Rots, M.G.; Trautwein, C.; Kimura, T.; Haisma, H.J.; Molema, G. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGD-PEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res. Ther. 2006, 8, R32.pl
    dc.description.referencesOgawara, K.; Rots, M.G.; Kok, R.J.; Moorlag, H.E.; Van Loenen, A.M.; Meijer, D.K.; Haisma, H.J.; Molema, G. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 2004, 15, 433–443.pl
    dc.description.referencesNiu, G.; Xiong, Z.; Cheng, Z.; Cai, W.; Gambhir, S.S.; Xing, L.; Chen, X. In vivo bioluminescence tumor imaging of RGD peptide-modified adenoviral vector encoding firefly luciferase reporter gene. Mol. Imaging Biol. 2007, 9, 126–134.pl
    dc.description.referencesKim, P.H.; Kim, T.I.; Yockman, J.W.; Kim, S.W.; Yun, C.O. The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 2010, 31, 1865–1874.pl
    dc.description.referencesEto, Y.; Gao, J.Q.; Sekiguchi, F.; Kurachi, S.; Katayama, K.; Maeda, M.; Kawasaki, K.; Mizuguchi, H.; Hayakawa, T.; Tsutsumi, Y.; et al. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 2005, 7, 604–612.pl
    dc.description.referencesShen, J.; Meng, Q.; Sui, H.; Yin, Q.; Zhang, Z.; Yu, H.; Li, Y. iRGD conjugated TPGS mediates codelivery of paclitaxel and survivin shRNA for the reversal of lung cancer resistance. Mol. Pharm. 2014, 11, 2579–2591.pl
    dc.description.referencesSchiffelers, R.M.; Ansari, A.; Xu, J.; Zhou, Q.; Tang, Q.; Storm, G.; Molema, G.; Lu, P.Y.; Scaria, P.V.; Woodle, M.C. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 2004, 32, e149.pl
    dc.description.referencesChristie, R.J.; Matsumoto, Y.; Miyata, K.; Nomoto, T.; Fukushima, S.; Osada, K.; Halnaut, J.; Pittella, F.; Kim, H.J.; Nishiyama, N.; et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 2012, 6, 5174–5189.pl
    dc.description.referencesMalhotra, M.; Tomaro-Duchesneau, C.; Saha, S.; Prakash, S. Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. Int. J. Biomater. 2013, 2013, 252531.pl
    dc.description.referencesDou, S.; Yang, X.Z.; Xiong, M.H.; Sun, C.Y.; Yao, Y.D.; Zhu, Y.H.; Wang, J. ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2+ breast cancer. Adv. Healthc. Mater. 2014, 3, 1792–1803.pl
    dc.description.referencesHan, L.; Tang, C.; Yin, C. Dual-targeting and pH/redox-responsive multi-layered nanocomplexes for smart co-delivery of doxorubicin and siRNA. Biomaterials 2015, 60, 42–52.pl
    dc.description.referencesGao, L.Y.; Liu, X.Y.; Chen, C.J.; Wang, J.C.; Feng, Q.; Yu, M.Z.; Ma, X.F.; Pei, X.W.; Niu, Y.J.; Qiu, C.; et al. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Biomaterials 2014, 35, 2066–2078.pl
    dc.description.referencesBartlett, D.W.; Davis, M.E. Impact of tumor-specific targeting and dosing schedule on tumor growth inhibition after intravenous administration of siRNA-containing nanoparticles. Biotechnol. Bioeng. 2008, 99, 975–985.pl
    dc.description.referencesParker, A.L.; Fisher, K.D.; Oupicky, D.; Read, M.L.; Nicklin, S.A.; Baker, A.H.; Seymour, L.W. Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. J. Drug Target. 2005, 13, 39–51.pl
    dc.description.volume25pl
    dc.description.issue11pl
    dc.description.firstpage6219pl
    dc.description.lastpage6249pl
    dc.identifier.citation2International Journal of Molecular Sciencespl
    dc.identifier.orcidbrakorcid-
    dc.identifier.orcid0000-0002-5478-8732-
    dc.identifier.orcidbrakorcid-
    dc.identifier.orcid0000-0001-6191-6053-
    dc.identifier.orcid0000-0001-8587-6711-
    dc.identifier.orcidbrakorcid-
    dc.identifier.orcidbrakorcid-
    Występuje w kolekcji(ach):Artykuły naukowe (WChem)

    Pliki w tej pozycji:
    Plik Opis RozmiarFormat 
    ijms-25-06219.pdf1,64 MBAdobe PDFOtwórz
    Pokaż uproszczony widok rekordu Zobacz statystyki


    Pozycja ta dostępna jest na podstawie licencji Licencja Creative Commons CCL Creative Commons